Hod Hasharon, Israel & Shanghai – September 07, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

HONG KONG -- September 01, 2026 -- Fosun International reported a 160.3% year-on-year surge in first-half profit attributable to owners of the parent to RMB1.72 billion, the conglomerate said at an interim results presentation held in Hong Kong on Aug. 28. Total revenue for the six-month period reached RMB86.96 billion, with overseas markets contributing RMB49.16 billion, or 56.5% of the total.